Evanescence wave-based technology for the rapid and sensitive quantification of biological analytes - 28/02/18

| Disclosure of potential conflict of interest: M. Schawaller is employed by, has received travel support from, and is cofounder and shareholder of Davos Diagnostics. C. Rhyner is employed by the Swiss Institute for Allergy and Asthma Research and Davos Diagnostics, has received grants from Kommission für technologische Innovation (KTI), and has stock/stock options in DDX. M. Wiki has received grants from EU FP 7 (RaptaDiag 304814) and KTI (PFLS-LS 13066.1, PFLS-LS 16009.1). G. Quapil has patents paid to Davos Diagnostics licensed to Leuze Electronic. T. Zuberbier has consultant arrangements with ALK, Almirall, Abbvie, Astellas, Bayer Health Care, Bencard, Berlin Chemie, FAES, HAL, Henkel, Kryolan, Leti, Meda, Menarini, Merck, MSD, Novartis, Pharmasquire, Quintiles, Serono, Stallergenes, Takeda, Teva, and UCB; and has the following organizational affiliations: Committee member, WHO-Initiative “Allergic Rhinitis and its Impact on Asthma” (ARIA); Member of the Board, German Society for Allergy and Clinical Immunology (DGAKI); Head, European Centre for Allergy Research Foundation; Secretary General, Global Allergy and Asthma European Network (GA2LEN); and Member, Committee on Allergy Diagnosis and Molecular Allergology, World Allergy Organisation. C. A. Akdis has received grants from Actellion, EU FP 7 Projects Medall and Predicta, Allergopharma, the Swiss National Science Foundation, and the Christine Kühne Center for Allergy Research and Education. R. Crameri has received a grant and travel support from the Swiss National Science Foundation and is cofounder and shareholder of Davos Diagnostics AG. |
Vol 141 - N° 2
P. 817 - février 2018 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
